Concept
Tobacco smoke exposure
5 studies
Tobacco exposure covers smoked cigarettes, secondhand smoke, and smokeless tobacco as causes or correlates of reproductive, cardiovascular, and occupational harm—studied with dose–response birth data, multi-outcome risk functions, subtype-specific CVD epidemiology, and population SLT prevalence.
Students often treat “tobacco is bad” as one smoked-cigarette claim. Prenatal dose–response for preterm birth, conservative SHS risk floors, active-smoking CVD subtype maps, and smokeless-tobacco occupational patterns are different evidence jobs.
Studies
5
Findings
5
5 supporting · 0 challenging · 6 qualifying citations
Open tensions
3
Currently
What we know
- Even low-intensity maternal smoking raises preterm-birth odds; quitting before pregnancy looks like never-smoking risk.
- Conservative Burden of Proof methods still link SHS to multiple adult/child outcomes.
- Active tobacco smoking maps onto many CVD subtypes, not only “heart disease” as one bucket.
- In older Indian adults, smokeless tobacco is common and clusters in rural, male, poorer, and informal work.
- India’s tobacco epidemic rose then fell for men while women declined, with huge state gaps and smokeless still common.
Largest unresolved question
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
Common misconceptions
Light smoking in pregnancy is harmless if you cut down.
Low-intensity trimester smoking still raised preterm-birth odds versus nonsmokers in the cited birth data.
Secondhand smoke risks are too weak to matter once you use conservative methods.
Burden of Proof still found positive risk floors for several outcomes, even when evidence strength was only moderate (star ratings).
If someone does not smoke cigarettes, tobacco harm is not an issue.
In LASI, smokeless tobacco was the majority product among tobacco users; occupation and rural male informal work tracked higher SLT use.
Related
Claim ledger
What the evidence shows
Drawn from 5 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
Even low-intensity maternal smoking raises preterm-birth odds; quitting before pregnancy looks like never-smoking risk.
US birth-certificate analyses showed first-trimester smoking of 1–2 to ≥20 cigarettes/day associated with ORs ~1.31–1.53 for preterm birth; low-intensity smoking in either trimester still increased risk, while quitting before pregnancy tracked with never-smoker risk.
- How strong is the evidence that secondhand smoke harms health?— SHS Burden of Proof is environmental exposure in non-smokers — not maternal active-smoking dose on birth certificates
Study Role Design N Population Outcome Is any prenatal smoking safe for preterm birth? Supports CohortMaternal smoking before and during pregnancy vs preterm birth Perinatal cohort; single analytic N not extracted Pregnant women with recorded smoking status before and during pregnancy Preterm-birth risk associated with maternal cigarette smoking How strong is the evidence that secondhand smoke harms health? QualifiesSHS Burden of Proof is environmental exposure in non-smokers — not maternal active-smoking dose on birth certificates Meta-analysis / systematic reviewBurden of Proof Risk Function systematic review/meta-analysis of SHS vs nine outcomes N=410 · 410 publications with SHS relative risks after screening 7,109+ records Observational studies of secondhand smoke exposure and selected diseases Conservative risk increases and star-rated evidence strength for nine outcomes Conservative Burden of Proof methods still link SHS to multiple adult/child outcomes.
A Burden of Proof synthesis associated SHS with nine outcomes; conservative floors included ≥~8% higher IHD, ≥~5% stroke, and smaller but positive floors for type 2 diabetes and lung cancer (two-star ratings), with additional child respiratory and other endpoints.
- How broadly does smoking raise heart and vessel disease risk?— active smoking CVD subtype risks are larger/different exposure than SHS
Study Role Design N Population Outcome How strong is the evidence that secondhand smoke harms health? Supports Meta-analysis / systematic reviewBurden of Proof Risk Function systematic review/meta-analysis of SHS vs nine outcomes N=410 · 410 publications with SHS relative risks after screening 7,109+ records Observational studies of secondhand smoke exposure and selected diseases Conservative risk increases and star-rated evidence strength for nine outcomes How broadly does smoking raise heart and vessel disease risk? Qualifiesactive smoking CVD subtype risks are larger/different exposure than SHS Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status Active tobacco smoking maps onto many CVD subtypes, not only “heart disease” as one bucket.
Large cohort evidence linked tobacco smoking to risk across dozens of fatal and non-fatal cardiovascular disease subtypes.
- Is any prenatal smoking safe for preterm birth?— reproductive preterm endpoint ≠ adult CVD subtype incidence
Study Role Design N Population Outcome How broadly does smoking raise heart and vessel disease risk? Supports Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status Is any prenatal smoking safe for preterm birth? Qualifiesreproductive preterm endpoint ≠ adult CVD subtype incidence CohortMaternal smoking before and during pregnancy vs preterm birth Perinatal cohort; single analytic N not extracted Pregnant women with recorded smoking status before and during pregnancy Preterm-birth risk associated with maternal cigarette smoking In older Indian adults, smokeless tobacco is common and clusters in rural, male, poorer, and informal work.
LASI wave 1 (n=65,561) found 38% ever tobacco use; 22.8% ever and 20.4% currently used smokeless tobacco. Among tobacco users, 51% used SLT, 40% smoked, and 9% used both. Use was higher in Scheduled Tribe groups and in agricultural/plant-machine work (~22%) than among professionals (~10%); 88.6% of ever-SLT users still used it.
- How broadly does smoking raise heart and vessel disease risk?— active smoked-tobacco CVD subtype risks are a different product and endpoint than SLT occupational prevalence
Study Role Design N Population Outcome Who uses smokeless tobacco in India’s LASI sample? Supports Cross-sectionalLASI wave 1 (2017–18) nationally representative survey-weighted descriptives and multivariable logistic regression of smokeless tobacco by occupation N=65561 · LASI wave 1 sample of 65,561 adults; 24,777 (38%) ever used smoked or smokeless tobacco Indian adults in the Longitudinal Aging Study in India wave 1 (mostly ages 45+) Ever/current smokeless tobacco use and occupational plus childhood-adversity correlates How broadly does smoking raise heart and vessel disease risk? Qualifiesactive smoked-tobacco CVD subtype risks are a different product and endpoint than SLT occupational prevalence Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status India’s tobacco epidemic rose then fell for men while women declined, with huge state gaps and smokeless still common.
NFHS rounds showed age-standardized male tobacco use rising 32% from 1998–99 to 2005–06 (27.90% to 36.81%) then falling 26% by 2015–16 (to 27.31%); women’s use declined throughout. By 2015–16 male smoking was 12.20% and smokeless 15.12%, with male smoking from 5.71% (Maharashtra) to 37.70% (Mizoram).
- Who uses smokeless tobacco in India’s LASI sample?— LASI older-adult SLT occupation prevalence — not NFHS 15–49 time-trend smoking vs smokeless
- How broadly does smoking raise heart and vessel disease risk?— Western smoked-tobacco CVD subtype risks ≠ Indian national prevalence trends
Study Role Design N Population Outcome Did India’s tobacco epidemic peak and recede? Supports Cross-sectionalRepeated nationally representative NFHS-2/3/4 household surveys (1998–2016) with age-standardized smoking and smokeless tobacco prevalence for ages 15–49 by sex and state N=601509 · NFHS-4 interviewed 601,509 households (2015-16); NFHS-2 91,196; NFHS-3 109,041; analysis of men and women aged 15–49 Indian men and women aged 15–49 in 27 states and two union territories covering 99% of the population Age-standardized prevalence of any tobacco, smoking, and smokeless tobacco, nationally and by state, 1998–2016 Who uses smokeless tobacco in India’s LASI sample? QualifiesLASI older-adult SLT occupation prevalence — not NFHS 15–49 time-trend smoking vs smokeless Cross-sectionalLASI wave 1 (2017–18) nationally representative survey-weighted descriptives and multivariable logistic regression of smokeless tobacco by occupation N=65561 · LASI wave 1 sample of 65,561 adults; 24,777 (38%) ever used smoked or smokeless tobacco Indian adults in the Longitudinal Aging Study in India wave 1 (mostly ages 45+) Ever/current smokeless tobacco use and occupational plus childhood-adversity correlates How broadly does smoking raise heart and vessel disease risk? QualifiesWestern smoked-tobacco CVD subtype risks ≠ Indian national prevalence trends Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
- Is any prenatal smoking safe for preterm birth?
- How strong is the evidence that secondhand smoke harms health?
- How broadly does smoking raise heart and vessel disease risk?
Study Role Design N Population Outcome Is any prenatal smoking safe for preterm birth? Supports CohortMaternal smoking before and during pregnancy vs preterm birth Perinatal cohort; single analytic N not extracted Pregnant women with recorded smoking status before and during pregnancy Preterm-birth risk associated with maternal cigarette smoking How strong is the evidence that secondhand smoke harms health? Supports Meta-analysis / systematic reviewBurden of Proof Risk Function systematic review/meta-analysis of SHS vs nine outcomes N=410 · 410 publications with SHS relative risks after screening 7,109+ records Observational studies of secondhand smoke exposure and selected diseases Conservative risk increases and star-rated evidence strength for nine outcomes How broadly does smoking raise heart and vessel disease risk? Supports Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status
Qualified studies asking the same question reach different answers. The disagreement is listed, not scored.
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
- Who uses smokeless tobacco in India’s LASI sample?
- How broadly does smoking raise heart and vessel disease risk?
- How strong is the evidence that secondhand smoke harms health?
Study Role Design N Population Outcome Who uses smokeless tobacco in India’s LASI sample? Supports Cross-sectionalLASI wave 1 (2017–18) nationally representative survey-weighted descriptives and multivariable logistic regression of smokeless tobacco by occupation N=65561 · LASI wave 1 sample of 65,561 adults; 24,777 (38%) ever used smoked or smokeless tobacco Indian adults in the Longitudinal Aging Study in India wave 1 (mostly ages 45+) Ever/current smokeless tobacco use and occupational plus childhood-adversity correlates How broadly does smoking raise heart and vessel disease risk? Supports Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status How strong is the evidence that secondhand smoke harms health? Supports Meta-analysis / systematic reviewBurden of Proof Risk Function systematic review/meta-analysis of SHS vs nine outcomes N=410 · 410 publications with SHS relative risks after screening 7,109+ records Observational studies of secondhand smoke exposure and selected diseases Conservative risk increases and star-rated evidence strength for nine outcomes
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
- Did India’s tobacco epidemic peak and recede?
- Who uses smokeless tobacco in India’s LASI sample?
- How broadly does smoking raise heart and vessel disease risk?
Study Role Design N Population Outcome Did India’s tobacco epidemic peak and recede? Supports Cross-sectionalRepeated nationally representative NFHS-2/3/4 household surveys (1998–2016) with age-standardized smoking and smokeless tobacco prevalence for ages 15–49 by sex and state N=601509 · NFHS-4 interviewed 601,509 households (2015-16); NFHS-2 91,196; NFHS-3 109,041; analysis of men and women aged 15–49 Indian men and women aged 15–49 in 27 states and two union territories covering 99% of the population Age-standardized prevalence of any tobacco, smoking, and smokeless tobacco, nationally and by state, 1998–2016 Who uses smokeless tobacco in India’s LASI sample? Supports Cross-sectionalLASI wave 1 (2017–18) nationally representative survey-weighted descriptives and multivariable logistic regression of smokeless tobacco by occupation N=65561 · LASI wave 1 sample of 65,561 adults; 24,777 (38%) ever used smoked or smokeless tobacco Indian adults in the Longitudinal Aging Study in India wave 1 (mostly ages 45+) Ever/current smokeless tobacco use and occupational plus childhood-adversity correlates How broadly does smoking raise heart and vessel disease risk? Supports Cohort45 and Up Study; current and past vs never smokers for fatal/non-fatal CVD subtypes N=188167 · Analysis dataset 188,167 participants; 27,511 major CVD events over 1.35 million person-years Australian adults in the 45 and Up Study Hospitalisation or death from major CVD subtypes by smoking status
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Tobacco smoke exposure
Added a misconception
If someone does not smoke cigarettes, tobacco harm is not an issue.
- Added a scope qualifier
How broadly does smoking raise heart and vessel disease risk?
- Added a scope qualifier
Who uses smokeless tobacco in India’s LASI sample?
- Added a scope qualifier
How broadly does smoking raise heart and vessel disease risk?
- Added a supporting study
Who uses smokeless tobacco in India’s LASI sample?
- Added a supporting study
How strong is the evidence that secondhand smoke harms health?
- Added a supporting study
Who uses smokeless tobacco in India’s LASI sample?
- Added a supporting study
How broadly does smoking raise heart and vessel disease risk?
- Added a supporting study
Did India’s tobacco epidemic peak and recede?
- Added a supporting study
Who uses smokeless tobacco in India’s LASI sample?
- Added a supporting study
Did India’s tobacco epidemic peak and recede?
- Added a supporting study
How broadly does smoking raise heart and vessel disease risk?
New claim
LASI wave 1 (n=65,561) found 38% ever tobacco use; 22.8% ever and 20.4% currently used smokeless tobacco. Among tobacco users, 51% used SLT, 40% smoked, and 9% used both. Use was higher in Scheduled Tribe groups and in agricultural/plant-machine work (~22%) than among professionals (~10%); 88.6% of ever-SLT users still used it.
New claim
NFHS rounds showed age-standardized male tobacco use rising 32% from 1998–99 to 2005–06 (27.90% to 36.81%) then falling 26% by 2015–16 (to 27.31%); women’s use declined throughout. By 2015–16 male smoking was 12.20% and smokeless 15.12%, with male smoking from 5.71% (Maharashtra) to 37.70% (Mizoram).
New tension
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
New tension
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
LASI wave 1 (n=65,561) found 38% ever tobacco use; 22.8% ever and 20.4% currently used smokeless tobacco. Among tobacco users, 51% used SLT, 40% smoked, and 9% used both. Use was higher in Scheduled Tribe groups and in agricultural/plant-machine work (~22%) than among professionals (~10%); 88.6% of ever-SLT users still used it.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Who uses smokeless tobacco in India’s LASI sample?
- Coverage updated · Added a scope qualifier: How broadly does smoking raise heart and vessel disease risk?
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
- Coverage updated · New tension
- Coverage updated · Added a supporting study: How strong is the evidence that secondhand smoke harms health?
- Coverage updated · Added a supporting study: Who uses smokeless tobacco in India’s LASI sample?
- Coverage updated · Added a supporting study: How broadly does smoking raise heart and vessel disease risk?
If someone does not smoke cigarettes, tobacco harm is not an issue.
- Coverage updated · Added a misconception
NFHS rounds showed age-standardized male tobacco use rising 32% from 1998–99 to 2005–06 (27.90% to 36.81%) then falling 26% by 2015–16 (to 27.31%); women’s use declined throughout. By 2015–16 male smoking was 12.20% and smokeless 15.12%, with male smoking from 5.71% (Maharashtra) to 37.70% (Mizoram).
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Did India’s tobacco epidemic peak and recede?
- Coverage updated · Added a scope qualifier: Who uses smokeless tobacco in India’s LASI sample?
- Coverage updated · Added a scope qualifier: How broadly does smoking raise heart and vessel disease risk?
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
- Coverage updated · New tension
- Coverage updated · Added a supporting study: Who uses smokeless tobacco in India’s LASI sample?
- Coverage updated · Added a supporting study: Did India’s tobacco epidemic peak and recede?
- Coverage updated · Added a supporting study: How broadly does smoking raise heart and vessel disease risk?
- Coverage updated · Concept page published
Papers
5 studies in this library bear on Tobacco smoke exposure, ordered by citations.
- How broadly does smoking raise heart and vessel disease risk?
In a large Australian cohort, current smoking raised risk across nearly all CVD subtypes—especially peripheral arterial disease—and quitting lowered risk.
- Is any prenatal smoking safe for preterm birth?
Among 25.6 million US births, even 1–2 cigarettes/day in the first or second trimester raised preterm-birth odds; quitting before pregnancy matched nonsmoker risk.
- How strong is the evidence that secondhand smoke harms health?
Across 410 studies, SHS linked to all nine outcomes; conservative floors were ~8% higher IHD, 5% stroke, and 1% each for T2D and lung cancer (two-star evidence).
- Did India’s tobacco epidemic peak and recede?
Across NFHS rounds, age-standardized tobacco use in Indian men rose 32% from 1998-99 to 2005-06 (27.90% to 36.81%) then fell 26% by 2015-16 (to 27.31%), while women’s use declined throughout—yet 2015-16 levels still looked like 1998-99, with huge state gaps.
- Who uses smokeless tobacco in India’s LASI sample?
Among 65,561 LASI adults, 38% had used any tobacco; 22.8% ever and 20.4% currently used smokeless tobacco, with higher use in rural, male, poorer, ST, and informal/agricultural work.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
Maternal cigarette dose and preterm birth odds vs Conservative SHS relative-risk floors across outcomes vs Active smoking across CVD subtypes
Smokeless-tobacco prevalence by occupation in India is not a smoked-cigarette CVD risk function and is not a secondhand-smoke Burden of Proof synthesis. Product, population, and outcome all differ.
National NFHS time trends, LASI occupational SLT prevalence, and smoked-tobacco CVD relative risks describe different products, ages, and outcomes.
Ask PaperFren about Tobacco smoke exposure
Study this conceptflashcards and short-answer questions
What happened to preterm-birth risk when people quit smoking before pregnancy in the NVSS analysis?
Risk looked comparable to never smokers (unlike continuing smokers).
Name two outcome classes linked to SHS in the Burden of Proof study.
Examples: IHD/stroke; type 2 diabetes; lung cancer; child otitis/asthma/LRI; COPD; breast cancer (as reported).
Why can’t Indian SLT prevalence be pooled with UK/US smoked-tobacco CVD relative risks as one “tobacco effect”?
Different products (chewed/oral vs smoked), different outcomes (prevalence/occupation vs incident CVD subtypes), and different populations; pooling invents a common effect the designs do not estimate.
Flashcards
0 of 1 answers reviewed